EGFR and non-small cell lung carcinoma: Although RELAY demonstrates the safety and efficacy of first-line combination treatment with ramucirumab 10 mg/kg Q2W plus erlotinib (150 mg/day) in EGFR-mutated metastatic NSCLC, this analysis is limited by several factors.